SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) major shareholder Orbimed Advisors Llc sold 371 shares of the stock in a transaction on Monday, June 7th. The shares were sold at an average price of $84.90, for a total value of $31,497.90. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Orbimed Advisors Llc also recently made the following trade(s):
- On Wednesday, June 9th, Orbimed Advisors Llc sold 5,049 shares of SpringWorks Therapeutics stock. The shares were sold at an average price of $85.33, for a total value of $430,831.17.
Shares of NASDAQ:SWTX opened at $83.97 on Friday. The stock has a 50-day simple moving average of $74.36. SpringWorks Therapeutics, Inc. has a 12-month low of $35.20 and a 12-month high of $96.48. The firm has a market cap of $4.12 billion, a price-to-earnings ratio of -61.74 and a beta of 0.71.
A number of analysts recently commented on SWTX shares. The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 price objective on shares of SpringWorks Therapeutics in a research note on Monday, March 22nd. Zacks Investment Research lowered SpringWorks Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, May 12th. HC Wainwright raised their price target on SpringWorks Therapeutics from $101.00 to $124.00 and gave the stock a “buy” rating in a research note on Thursday, February 25th. Finally, Barclays raised their price target on SpringWorks Therapeutics from $92.00 to $105.00 and gave the stock an “overweight” rating in a research note on Friday, February 26th. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $95.67.
Several institutional investors have recently added to or reduced their stakes in the company. Citadel Advisors LLC raised its holdings in shares of SpringWorks Therapeutics by 1.1% in the 1st quarter. Citadel Advisors LLC now owns 801,391 shares of the company’s stock worth $58,958,000 after purchasing an additional 8,605 shares during the period. Voloridge Investment Management LLC raised its holdings in shares of SpringWorks Therapeutics by 332.9% in the 1st quarter. Voloridge Investment Management LLC now owns 51,757 shares of the company’s stock worth $3,808,000 after purchasing an additional 39,800 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in shares of SpringWorks Therapeutics by 122.3% in the 1st quarter. D. E. Shaw & Co. Inc. now owns 150,241 shares of the company’s stock worth $11,053,000 after purchasing an additional 82,667 shares during the period. Morgan Stanley raised its holdings in shares of SpringWorks Therapeutics by 83.0% in the 1st quarter. Morgan Stanley now owns 133,866 shares of the company’s stock worth $9,849,000 after purchasing an additional 60,696 shares during the period. Finally, Tudor Investment Corp Et Al purchased a new stake in shares of SpringWorks Therapeutics during the 1st quarter valued at about $591,000. Institutional investors own 88.50% of the company’s stock.
About SpringWorks Therapeutics
SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.
Featured Article: What are the advantages to having securities held in street name?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.